<DOC>
	<DOCNO>NCT01991249</DOCNO>
	<brief_summary>Acute leukemias heterogeneous group hematologic malignancy . They result clonal expansion immature cell whose number great 20 % bone marrow . Childhood acute leukemia common pediatric malignancy . In Europe United state , represent 35 % childhood cancer . 80 % acute lymphoblastic leukemia ( ALL ) 15-20 % acute myeloid leukemia ( AML ) . Current treatment allow cure 80 % ALL , level 50 % AML.Acute leukemia diagnosis base multidisciplinary exploration leukemia cell different technique : - Cellular : cytology , immunophenotyping cytochemistry - Cytogenetic : conventional ( karyotype ) molecular ( FISH ) cytogenetic - Molecular : RT-PCR RQ-PCR Cytogenetic study perform time acute leukemia diagnosis . Indeed , WHO 2008 classification acute leukemia base largely presence recurrent cytogenetic molecular abnormality . The frequent chromosomal aberration associate specific clinical biological characteristic use diagnosis prognostic marker . These chromosomal abnormality affect gene involve leukemogenesis process . These rearrangement several type : - Fusion gene cause : - Repression transcriptional activity gene involve differentiation hematopoietic cell ( AML1-ETO , PML-RARA… ) - Deregulation signal transduction pathway ( eg BCR-ABL chimeric protein constitutive tyrosine kinase activity ) - Changing state chromatin condensation result change transcription ( MLL gene rearrangement 11q23 , MOZ en 8p11… ) - Deregulation gene expression : chromosomal rearrangement sometimes induce deregulation adjacent gene breakpoint . For example , inv ( 3 ) ( q21q26 ) ( 3 ; 3 ) ( q21 ; q26 ) induce expression transcriptional factor EVI-1 . - Loss function due deletion variable size genomic region contain gene role differentiation , apoptosis , cell proliferation ( eg IKZF1 , PAX5… ) In addition karyotype , allow global view genome ; FISH , target technique , use highlight invisible abnormality karyotype ( cryptic abnormality ) time karyotype failure . However , conventional molecular cytogenetic technique highlight abnormality ( eg different partner involve formation fusion gene particular MLL gene rearrangement , mutation ) hence interest next generation sequencing.Indeed , high throughput target sequence messenger RNAs ( RNA-seq ) avantage allow identification different type mutation single test , exception epigenetic mutation . The importance RNAs sequence rather DNA genomic one hand , significant decrease volume sequence analyze transcribe mRNA gene represent 5 % genome size secondly , good identification chimeric gene . The RNA-seq use research tool hematologic malignancy . The purpose project use innovative technology develop new diagnostic prognostic new tool hematological malignancy . 50 acute leukemia test result analyze accord three criterion : - Quantity , quality relevance information provide diagnosis , monitor therapeutic management compare conventional strategy - Period require obtain result method decrease analysis time result integrate therapeutic decision . - Economic evaluation , calculate cost diagnosis option ass cost/benefit ratio In future , innovative approach implement ( study imbalance genomic abnormality array-CGH , transcriptome analysis micro-array , study methylome ) identify `` molecular signature '' leukemia set informative abnormality diagnosis , prognosis treatment disease monitor residual disease .</brief_summary>
	<brief_title>Targeted High Throughput Sequencing Diagnosis Pediatric Acute Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<criteria>patient age 018 year diagnosis acute leukemia patient without leukemia diagnosis patient quantity obtain DNA RNA insufficient</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>pediatric acute leukemia</keyword>
	<keyword>Targeted high throughput sequence</keyword>
	<keyword>messenger RNA</keyword>
</DOC>